A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.

Pfizer1,112 enrolled

Overview

The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.

Study Type

OBSERVATIONAL

Enrollment

1,112

Conditions

Renal Cell Cancer Renal Cell Carcinoma Cancer of Kidney Cancer of the Kidney Kidney Cancer Kidney Neoplasms Renal Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: For the characteristic group: * Diagnosis of renal cell carcinoma (International Classification of Diseases 10th revision \[ICD\]-10:64) during 01 January 2010 and 31 December 2021 For the mRCC group: * ICD-10 diagnosis code for metastasis (C77\*-C79\*), or * American Joint Committee on Cancer (AJCC) stage 4, or AJCC stage data potentially not available for all patients * Visit to oncologist (specialty code 65) with RCC as main diagnosis, or In Finland, the ICD-10 codes for metastatic disease are rarely used. In contrast, RCC patients visit oncologist, when and only when disease metastasises and therefore, the visit can be used as a proxy to a metastatic disease * Initiation of treatment for mRCC Exclusion Criteria: For the characteristic group: * Prevalent mRCC patients (i.e. diagnosis of metastatic RCC before 01 January 2010) * Prevalent mRCC patients (i.e. diagnosis of RCC before 01 January 2010) if there is no records of metastatic disease during 2010-2021 For the mRCC group: * Prevalent patients with mRCC (i.e. diagnosis of metastatic RCC before 01 January 2010) * Patients without treatment for mRCC

Locations (1)

Pfizer Finland

Helsinki, Finland

Outcomes

Primary Outcomes

Number of Participants According to Co-Diagnoses Before Index

Number of participants according to co-diagnoses 3 years before participant's index were reported in this outcome measure. Index date was defined as the date of treatment initiation for mRCC. Co-diagnoses were based on International Classification of Diseases 10th revision (ICD-10) codes. One participant may have more than one co-diagnoses.

Time frame: 3 years prior to index date

Number of Participants According to Co-Diagnoses After Index

Number of participants according to co-diagnoses up to 3 years after participant's index were reported in this outcome measure. Index date was defined as the date of treatment initiation for mRCC. Co-diagnoses were based on ICD-10 codes. One participant may have more than one co-diagnoses.

Time frame: Up to 3 years after index date

Body Mass Index (BMI)

BMI of participants at index was reported in this outcome measure. Index date was defined as the date of treatment initiation for mRCC.

Time frame: At index

Mean Outpatient Visits and Emergent Room Visits Per Patient Year

The number of outpatient visits and emergency room (ER) visits per patient year for all contacts, disease-specific contacts and other contacts were reported in this outcome measure. All contacts included disease specific contacts and other contacts. Per patient year was defined as total sum of events divided by the total sum of follow-up length of the participants.

Time frame: Up to maximum of 12 years (retrospective data collection of 1 month)

Mean Number of Hospitalizations Per Patient Year

The number of hospitalization visits per patient year for all contacts, disease-specific contacts and other contacts were reported in this outcome measure. All contacts included disease specific contacts and other contacts. Per patient year was defined as total sum of events divided by the total sum of follow-up length of the participants.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Number of Participants Classified According to Karnofsky Performance Status (KPS) Stratified by IMDC Risk Category

KPS:used for rating activities of daily living on 11-step scale from 0-100,higher score=participant better able to carry daily activities.Score:100=normal no complaints;no disease evidence,90=able to carry normal activity;minor signs/symptoms of disease,80=normal activity with effort;some signs/symptoms, 70=cares for self;unable to carry normal activity,60=required occasional assistance,able to care for personal needs,50=required considerable assistance \& frequent medical care,40=disabled;required special care/assistance,30=severely disabled;hospital admission indicated;20=very sick;hospital admission necessary,10=moribund \& 0=dead.IMDC risk category:0=favorable risk,no missing values allowed;1-2=intermediate risk,total score=1:max 1 risk factor could have missing value,total score=2:no missing values allowed;3-6=poor risk,max 3 risk factors allowed to have missing values; Unknown=none of the above risk categories could be assigned.Index date=date of treatment initiation for mRCC.

Time frame: At index